特讯热点！职工医保个人账户资金共济新规：如何让家人共享医疗保障？

职工医保个人账户资金共济新规：如何让家人共享医疗保障？

[城市，日期] - 随着我国职工医保制度改革的不断深入，职工医保个人账户资金共济政策已于2024年5月1日起正式实施。该政策旨在提高医保基金使用效率，减轻参保职工个人医疗费用负担，并实现家庭成员之间医疗保障的有效共享。

**根据新规，职工医保参保人员可以将个人账户资金共济给其配偶、父母、子女等家庭成员。**具体而言，共济对象包括：

• 参保职工的配偶；
• 参保职工的父母；
• 参保职工的子女（未成年子女、在校学生、已毕业未就业子女）。

职工医保个人账户资金共济的方式有两种：

• **授权委托方式：**参保职工可以通过医保经办机构授权委托其家庭成员使用个人账户资金。
• **代扣划拨方式：**参保职工家庭成员在就医购药时，可以使用参保职工的个人账户资金进行直接扣划。

职工医保个人账户资金共济的具体流程如下：

• 参保职工本人携带身份证、医保卡等相关材料，前往医保经办机构办理授权委托或代扣划拨手续。
• 参保职工家庭成员在就医购药时，携带参保职工的医保卡和本人身份证件，即可使用参保职工的个人账户资金进行结算。

**需要注意的是，职工医保个人账户资金共济仅限于支付参保人员及其家庭成员在定点医疗机构发生的合规医疗费用。**具体包括：

• 住院医疗费用；
• 门诊医疗费用（部分地区已开通）；
• 特殊门诊医疗费用（如慢特病、门诊大病等）。

**职工医保个人账户资金共济政策的实施，有利于提高医保基金的使用效率，减轻参保职工个人医疗费用负担，并实现家庭成员之间医疗保障的有效共享。**参保职工及其家庭成员应积极了解相关政策，并合理使用个人账户资金，享受医保待遇。

请注意：

• 本新闻稿仅供参考，不构成任何法律建议。
• 本新闻稿中的信息可能存在误差或遗漏。
• 建议您咨询相关医保经办机构获取最新政策信息。

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.